No Data
No Data
Aditxt's Target Acquisition Appili Therapeutics Announces Alignment With FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership With Broader Perspectives
Express News | Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership With Broader Perspectives
Aditxt Estimates It Will Require About $17M in Additional Cash to Fund Proposed Acquisition of Evofem >ADTX
Aditxt: Evofem Will Be Surviving Co and Wholly-Owned Subsidiary of Aditxt >ADTX
No Data
No Data